Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272284 | 0.84 | PTGS2 (0.44) | PTGS2ACLY | |
| SCHEMBL776672 | 0.84 | PTGS2 (0.45) | PTGS2 | |
| SCHEMBL2055456 | 0.80 | ACLY (0.38) | EPAS1ACLYRAPGEF4 | |
| SCHEMBL16235568 | 0.78 | CA1 (0.50) | PTGS2 | |
| SCHEMBL15352296 | 0.78 | EPAS1 (0.39) | EPAS1ACLYRAPGEF4 | |
| SCHEMBL24757946 | 0.76 | PTGS2 (0.40) | PTGS2ACLYRAPGEF4 | |
| SCHEMBL12387975 | 0.76 | PTGS2 (0.43) | PTGS2 | |
| SCHEMBL1172365 | 0.74 | PTGS2 (0.43) | PTGS2 | |
| SCHEMBL8215750 | 0.74 | PTGS2 (0.39) | EPAS1PTGS2 | |
| SCHEMBL24156063 | 0.74 | WDR5 (0.50) | EPAS1PTGS2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352725-A1 | QUINOXALINE-BASED LXR MODULATORS | Wyeth LLC (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| WO-2010054229-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH LLC (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| CN-101679311-A | Quinazoline compound | WYETH CORP | 2010-03-24 | — | — | CN | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| CN-101541751-A | Quinoline compounds | WYETH CORP (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120778-A1 | QUINOXALINE-BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | EPAS1 867/4885PTGS2 2590/4885ACLY 371/4885 |
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | EPAS1 2539/4885PTGS2 2501/4885ACLY 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.